CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Cystadrops (cysteamine ophthalmic) for corneal cystine deposits

Criteria and prior authorization/quantity limits for Cystadrops (cysteamine 0.37% ophthalmic solution) to treat corneal cystine crystal deposits in adults and children with cystinosis for Neighborhood Health Plan of Rhode Island (Medicaid scope).

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCystadrops (cysteamine ophthalmic) for corneal cystine deposits

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain documented diagnostic confirmation (leukocyte cystine or genetic testing) plus slit-lamp confirmation of corneal cystine deposits for prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 moinitial authorization duration

12 mocontinuation authorization duration

20 mL/moquantity limit

1 drop/eye QIDmaximum dosing

Coverage Criteria for Cystadrops (cysteamine ophthalmic)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

Authorization of up to 6 months is covered when ALL of the following are met:

Initial approval criteria

Criterion A: Diagnosis of cystinosis confirmed by the presence of increased cystine concentration in leukocytes or by genetic testing
Criterion B: Member has corneal cysteine deposits confirmed by a slit-lamp examination
Criterion C: Dose of medication does not exceed one drop in each eye, 4 times daily during waking hours
Criterion D: Prescribed by an ophthalmologist or other specialist in the treatment of cystinosis

Continuation Therapy

Authorization of up to 12 months for continuation may be granted when the following is met:

Continuation criterion: Member is responding positively to therapy as evidenced by improvement or stabilization of corneal cysteine crystal accumulations since starting Cystadrops

No explicit exclusions are listed in this policy document for Cystadrops (cysteamine ophthalmic solution 0.37%).

This policy does not include any statements labeling use of Cystadrops as not medically necessary. The document provides coverage criteria and prior authorization requirements without explicit noncoverage language.

Prior Authorization, Documentation, and Denial Triggers

Prior Authorization

Prior authorization required — Initial therapy

Initial authorization: Up to 6 months may be granted when diagnostic confirmation and prescribing prerequisites are documented.

Diagnosis confirmed by increased leukocyte cystine concentration or genetic testing
Slit-lamp confirmation of corneal cystine/cysteine deposits
Dose ≤ one drop in each eye, up to 4 times daily during waking hours
Prescribed by an ophthalmologist or specialist in cystinosis treatment

Prior Authorization

Renewal/Continuation requirements

Continuation/renewal: Authorization up to 12 months may be granted when there is documentation of a positive clinical response to therapy.

Member demonstrates improvement or stabilization of corneal cystine/cysteine crystal accumulations since starting therapy
Applies to all members, including new members on plan

Step Therapy

Step therapy

No step therapy requirements specified.

Documentation Required

Required documentation

Required documentation must be submitted to support initial and continuation authorization requests.

Confirmation of cystinosis by increased leukocyte cystine concentration or genetic testing
Slit-lamp exam documentation confirming corneal cystine/cysteine deposits
Medication dose and directions showing ≤ one drop per eye, up to 4 times daily
Prescribing clinician specialty (ophthalmologist or cystinosis specialist)
Clinical notes or ophthalmology follow-up demonstrating improvement or stabilization for renewals

Denial Risk

Denial triggers

Authorizations may be denied if required diagnostic confirmation or documentation is missing.

No documented confirmation of cystinosis by leukocyte cystine measurement or genetic testing
Absence of slit-lamp confirmation of corneal cystine/cysteine deposits
Missing documentation of prescribed dose or prescribing clinician specialty
For renewals: lack of documentation showing improvement or stabilization on therapy

Key Definitions

Confirmed diagnosis

Confirmed diagnosis of cystinosisDiagnosis confirmed by increased cystine concentration in leukocytes or by genetic testing

Required documentation sourceDocumentation must include leukocyte cystine measurement results or genetic test report

ApplicabilityRequired for initial authorization (up to 6 months) for treatment of corneal cystine crystal deposits

Corneal deposits confirmation

Corneal cystine deposits confirmationPresence of corneal cystine/cysteine deposits verified by slit-lamp examination

Clinical roleSlit-lamp exam is required evidence for initial authorization and to document corneal deposits

TimingMust be documented prior to or at time of initial authorization request